2-羟基-3-(3-硝基苯基)丙烯酸 | 143815-55-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-羟基-3-(3-硝基苯基)丙烯酸
• 英文名称: 2-hydroxy-3-(3-nitrophenyl)acrylic acid
• 英文别名: 2-hydroxy-3-(3-nitrophenyl)prop-2-enoic acid
• CAS: 143815-55-8
• 化学式: C₉H₇NO₅
• 分子量: 209.158
• InChiKey: VJUPBWYPUNQPRR-UHFFFAOYSA-N

物化性质

• 沸点：
  431.6±45.0 °C(Predicted)
• 密度：
  1.558±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  103
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-羟基-3-(3-硝基苯基)丙烯酸 在 sodium tetrahydroborate 、 sodium ethanolate 、 水 作用下， 以 甲醇 为溶剂， 反应 0.5h， 以57%的产率得到2-hydroxy-3-(3-nitrophenyl)propionic acid
  参考文献：
  名称：

  Compounds and Their Salts Specific to the PPAR Receptors and the EGF Receptors and Their Use in the Medical Field

  摘要：

  本发明涉及具有一般式（I）的化合物，其中R1和R2，可以相同也可以不同，选自包括-H或具有1至6个碳原子的直链或支链烷基基团，或者共同形成具有5或6个原子的芳香或脂肪环的群；Y和Z，可以相同也可以不同，选自包括-H，-OH，-COOH，-OR3，-CH(OR3)COOH的群，其中R3选自H，苯基，苄基，-CF3或-CF2CF3，乙烯基，烯丙基和具有1至6个碳原子的直链或支链烷基基团。

  公开号：

  US20090048343A1
• 作为产物：
  描述：

  2-methyl-4-[(E)-(3-nitrophenyl)methylidene]-1,3-oxazol-5(4H)-one 在 盐酸 作用下， 生成 2-羟基-3-(3-硝基苯基)丙烯酸
  参考文献：
  名称：

  Chemocontrolled reduction of aromatic α-ketoesters by NaBH4: Selective synthesis of α-hydroxy esters or 1,2-diols

  摘要：

  alpha-hydroxyesters 5a-g or diols 6a-g have been obtained in high yields by reduction of aromatic alpha-ketoesters 4 once or twice respectively by using NaBH4 as the reducer under suitable conditions. The use of a solvent that does not interact with the reagent allowed the double reduction to occur with only a slight excess of borohydride in very mild conditions. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0040-4039(97)00154-8

文献信息

• New synthetic strategies towards psammaplin A, access to natural product analogues for biological evaluation
  作者：Matthias G. J. Baud、Thomas Leiser、Franz-Josef Meyer-Almes、Matthew J. Fuchter

  DOI：10.1039/c0ob00824a

  日期：——

  New synthetic routes towards the natural product psammaplin A were developed with the particular view to preparing diverse analogues for biological assessment. These routes utilize cheap and commercially available starting materials, and allowed access to psammaplin A analogues not accessible via currently reported methods. Preliminary biological studies revealed these compounds to be the most potent non peptidic inhibitors of the enzyme histone deacetylase 1 (HDAC1, class I) discovered so far. Interestingly, psammaplin A and our synthetic analogues show class I selectivity in vitro, an important feature for the design and synthesis of future isoform selective inhibitors.

  开发了新的合成路线以制备天然产物海绵抑素A（psammaplin A）及其多样化的类似物，这些类似物用于生物学评估。这些路线采用廉价且商业可获得的起始原料，并能合成目前报道方法难以获得的psammaplin A类似物。初步生物学研究表明，这些化合物是目前所发现的最强效的非肽类组蛋白去乙酰化酶1（HDAC1，I类）抑制剂。有趣的是，psammaplin A及其我们的合成类似物在体外显示出I类选择性，这对于设计和合成未来同工型选择性抑制剂具有重要意义。
• Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field
  申请人：Giuliani International Limited

  公开号：US08153841B2

  公开（公告）日：2012-04-10

  The present invention relates to compounds comprising the general formula (I), in which R1 and R2, which may be identical or different, are selected from the group comprising —H or a linear or branched alkyl group having from 1 to 6 carbon atoms or together form an aromatic or aliphatic ring with 5 or 6 atoms; Y and Z, which may be identical or different, are selected from the group comprising —H, —OH, —COOH, —OR3, —CH(OR3)COOH, in which R3 is selected from H, phenyl, benzyl, —CF3 or —CF2CF3, vinyl, allyl and a linear or branched alkyl group having from 1 to 6 carbon atoms.

  本发明涉及具有通式（I）的化合物，其中R1和R2可能相同或不同，选自包括-H或具有1至6个碳原子的线性或支链烷基或共同形成具有5或6个原子的芳香或脂肪环的群体; Y和Z可能相同或不同，选自包括-H，-OH，-COOH，-OR3，-CH（OR3）COOH，其中R3选自H，苯基，苄基，-CF3或-CF2CF3，乙烯基，丙烯基和具有1至6个碳原子的线性或支链烷基。
• Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field
  申请人：Naccari Giancarlo

  公开号：US20130005813A1

  公开（公告）日：2013-01-03

  The present invention relates to compounds comprising the general formula (I), in which R 1 and R 2 , which may be identical or different, are selected from the group comprising —H or a linear or branched alkyl group having from 1 to 6 carbon atoms or together form an aromatic or aliphatic ring with 5 or 6 atoms; Y and Z, which may be identical or different, are selected from the group comprising —H, —OH, —COOH, —OR 3 , —CH(OR 3 )COOH, in which R 3 is selected from H, phenyl, benzyl, —CF 3 or —CF 2 CF 3 , vinyl, allyl and a linear or branched alkyl group having from 1 to 6 carbon atoms.

  本发明涉及通式（I）的化合物，其中R1和R2可以相同或不同，选自包括-H或具有1到6个碳原子的线性或支链烷基或共同形成具有5或6个原子的芳香或脂肪环的群体；Y和Z可以相同或不同，选自包括-H、-OH、-COOH、-OR3、-CH（OR3）COOH的群体，其中R3选自H、苯基、苄基、-CF3或-CF2CF3、乙烯基、丙烯基和具有1到6个碳原子的线性或支链烷基。
• COMPOUNDS AND THEIR SALTS SPECIFIC TO THE PPAR RECEPTORS AND THE EGF RECEPTORS AND THEIR USE IN THE MEDICAL FIELD
  申请人：Nogra Pharma Limited

  公开号：EP1910270B3

  公开（公告）日：2016-05-11
• Structure–activity relationship study of 4EGI-1, small molecule eIF4E/eIF4G protein–protein interaction inhibitors
  作者：Khuloud Takrouri、Ting Chen、Evangelos Papadopoulos、Rupam Sahoo、Eihab Kabha、Han Chen、Sonia Cantel、Gerhard Wagner、Jose A. Halperin、Bertal H. Aktas、Michael Chorev

  DOI：10.1016/j.ejmech.2014.03.034

  日期：2014.4

  Protein-protein interactions are critical for regulating the activity of translation initiation factors and multitude of other cellular process, and form the largest block of untapped albeit most challenging targets for drug development. 4EGI-1, (E/Z)-2-(2-(4-(3,4-dichlorophenyl)thiazol-2-yl)hydrazono)-3-(2-nitrophenyl)propanoic acid, is a hit compound discovered in a screening campaign of small molecule libraries as an inhibitor of translation initiation factors elF4E and eIF4G protein protein interaction; it inhibits translation initiation in vitro and in vivo. A series of 4EGI-1-derived thiazol-2-yl hydrazones have been designed and synthesized in order to delineate the structural latitude and improve its binding affinity to eIF4E, and increase its potency in inhibiting the eIF4E/eIF4G interaction. Probing a wide range of substituents on both phenyl rings comprising the 3-phenylpropionic acid and 4-phenylthiazolidine moieties in the context of both E- and Z-isomers of 4EGI-1 led to analogs with enhanced binding affinity and translation initiation inhibitory activities. (C) 2014 Elsevier Masson SAS. All rights reserved.